Cardiff Oncology Inc Stock

$4.07

2.16% yesterday

Nasdaq, Jul 11, 10:00 pm CET

ISIN

US14147L1089

Symbol

CRDF

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Health service provider

Overview Dividends Analysts Charts News Strategies

Cardiff Oncology Inc Stock price

$4.07

-0.44 9.76% 5Y

Nasdaq, Closing price Fri, Jul 11 2025

-0.09 2.16%

ISIN

US14147L1089

Symbol

CRDF

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Health service provider

Key metrics

Basic

Market capitalization

$270.8m

Enterprise Value

$190.9m

Net debt

positive

Cash

$79.9m

Shares outstanding

66.5m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

458.9 | 644.1

EV/Sales

323.5 | 454.0

EV/FCF

negative

P/B

3.8

Financial Health

Equity Ratio

85.4%

Return on Equity

-54.8%

ROCE

-72.9%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$590.0k | $420.4k

EBITDA

$-51.7m | -

EBIT

$-52.1m | $-59.3m

Net Income

$-48.9m | $-54.0m

Free Cash Flow

$-42.8m

Growth (TTM | estimate)

Revenue

-3.3% | -38.2%

EBITDA

-17.8% | -

EBIT

-17.6% | -22.0%

Net Income

-21.4% | -18.7%

Free Cash Flow

-39.6%

EPS

$-0.7

FCF per Share

$-0.6

Short interest

26.7%

Employees

Rev per Employee

$20.0k

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

Cardiff Oncology Inc Stock Analysis

Unlock Scores for Free

??

13 Analysts have issued a Cardiff Oncology Inc forecast:

11x Buy

85%

2x Hold

15%

More details on Analyst Estimates Including Price Targets

13 Analysts have issued a Cardiff Oncology Inc forecast:

Buy

85%

Hold

15%

Analyst Estimates with Stock Price Targets

Financial data from Cardiff Oncology Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	0.59 0.59	3% 3% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	13 13	2% 2% 2,266%
- Research and Development Expense	39 39	24% 24% 6,664%
EBITDA	-52 -52	18% 18% -8,764%
- Depreciation and Amortization	0.40 0.40	2% 2% 68%
EBIT (Operating Income) EBIT	-52 -52	18% 18% -8,831%
Net Profit	-49 -49	21% 21% -8,285%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Cardiff Oncology Inc Stock News

Positive

Seeking Alpha

●

15 days ago

Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity

Cardiff Oncology's recent trial data readout delay has unnerved the market, but I see this as a potential buying opportunity for speculative investors. Leadership change is not a major risk factor. The new CMO's pedigree suggests confidence in the company's prospects ahead of the catalyst. The delay could suggest an attempt to improve poor data, or an ability to add to already strong data by wa...

Neutral

Market Watch

●

25 days ago

Cardiff Oncology Names Roger Sidhu as Medical Chief

Sidhu joined Cardiff from Treadwell Therapeutics, where he was medical chief and acting chief executive officer. Previously, Sidhu spent nearly 10 years at Amgen.

Neutral

GlobeNewsWire

●

25 days ago

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

– Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development –

More Cardiff Oncology Inc News

Company Profile

Cardiff Oncology, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic Colorectal Cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer; Phase I clinical trial with various chemotherapies and targeted therapeutics, such as Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) used in leukemias, lymphomas, and solid tumor cancers. It primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

Head office	United States
CEO	Mark Erlander
Employees	33
Founded	1999
Website	cardiffoncology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now